New vaccine aims to fight deadly brain cancer
NCT ID NCT06622434
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a cancer vaccine for people with newly diagnosed glioblastoma, a serious brain cancer. The vaccine is designed to help the immune system attack tumor cells. About 35 participants will receive the vaccine after standard treatment. The goal is to see if it is safe and boosts the immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cancer vaccine targeting TERT and PTPRZ1 proteins
What this could lead to
If successful, this could lead to a new treatment option that helps control glioblastoma and extends survival.
What could go wrong
This is an early-phase trial with only 35 participants, so results may not apply to all patients. The vaccine may not trigger a strong enough immune response or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Neurology, Hopital Saint louis (APHP)
RECRUITINGParis, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of Neurology, Hopital de la Salpêtrière
RECRUITINGParis, Idf, 75013, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Neuro-oncology Department, La Timone Hospital
NOT_YET_RECRUITINGMarseille, Provence-Alpes-Côte d'Azur Region, 13005, France
Contact Phone: •••-•••-•••• Email: •••••@•••••